Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection
暂无分享,去创建一个
V. Gordeuk | M. Nouraie | M. Callaghan | C. Minniti | D. Manwani | Jin Han | A. Crouch | E. Klings | A. Zaidi | J. Glassberg | Gary D. Crouch | S. Carpenter | J. Simon | C. Jacobs
[1] Jessica S. Brown,et al. Characteristics of Persons Who Died with COVID-19 - United States, February 12-May 18, 2020. , 2020, MMWR. Morbidity and mortality weekly report.
[2] L. Schieve,et al. Coronavirus Disease among Persons with Sickle Cell Disease, United States, March 20–May 21, 2020 , 2020, Emerging infectious diseases.
[3] E. Flamarion,et al. Prognosis of patients with sickle cell disease and COVID-19: a French experience , 2020, The Lancet Haematology.
[4] D. Rees,et al. COVID-19 in patients with sickle cell disease - a case series from a UK Tertiary Hospital. , 2020, Haematologica.
[5] K. Khunti,et al. The impact of ethnicity on clinical outcomes in COVID-19: A systematic review , 2020, EClinicalMedicine.
[6] S. Renolleau,et al. Patients with sickle cell disease and suspected COVID‐19 in a paediatric intensive care unit , 2020, British journal of haematology.
[7] C. Rentsch,et al. Covid-19 by Race and Ethnicity: A National Cohort Study of 6 Million United States Veterans , 2020, medRxiv.
[8] L. Kucirka,et al. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure , 2020, Annals of Internal Medicine.
[9] Alberto Borghetti,et al. Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line , 2020, International Journal of Antimicrobial Agents.
[10] D. Tsitsikas,et al. COVID‐19 infection and sickle cell disease: a UK centre experience , 2020, British journal of haematology.
[11] J. Connors,et al. COVID-19 and its implications for thrombosis and anticoagulation , 2020, Blood.
[12] V. Gordeuk,et al. COVID‐19 infection in patients with sickle cell disease , 2020, British journal of haematology.
[13] J. Deux,et al. Rapid and severe Covid‐19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab , 2020, American journal of hematology.
[14] B. Biemond,et al. Vaso‐occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID‐19) , 2020, American journal of hematology.
[15] Xiaowei Yan,et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 , 2020, The New England journal of medicine.
[16] Virginia Corbett,et al. COVID‐19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient , 2020, American journal of hematology.
[17] T. West,et al. Covid-19 in Critically Ill Patients in the Seattle Region — Case Series , 2020, The New England journal of medicine.
[18] S. Lindstrom,et al. First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.
[19] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[20] B. Andrade,et al. Hydroxyurea alters circulating monocyte subsets and dampens its inflammatory potential in sickle cell anemia patients , 2019, Scientific Reports.
[21] I. Hambleton,et al. Causes of death and early life determinants of survival in homozygous sickle cell disease: The Jamaican cohort study from birth , 2018, PloS one.
[22] G. Kato. New insights into sickle cell disease: mechanisms and investigational therapies , 2016, Current opinion in hematology.
[23] I. Tannock,et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.
[24] C. Haywood,et al. Mortality Rates and Age at Death from Sickle Cell Disease: U.S., 1979–2005 , 2013, Public health reports.
[25] C. Scheiermann,et al. Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. , 2012, Blood.
[26] S. Weiss,et al. Coronavirus Pathogenesis , 2011, Advances in Virus Research.
[27] Mi‐Ok Kim,et al. The impact of the 2009 H1N1 influenza pandemic on pediatric patients with sickle cell disease , 2011, Pediatric blood & cancer.
[28] E. Vichinsky,et al. Novel influenza a (H1N1) viral infection in pediatric patients with sickle‐cell disease , 2011, Pediatric blood & cancer.
[29] J. Strouse,et al. Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell disease. , 2010, Blood.
[30] B. Biemond,et al. Acute chest syndrome in sickle cell disease due to the new influenza A (H1N1) virus infection , 2010, American journal of hematology.
[31] K. Eagle,et al. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. , 2008, The American journal of cardiology.
[32] M. Gladwin,et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease , 2002, British journal of haematology.